Overview

PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the pharmacokinetic (PK) profile of EXPAREL when administered via local wound infiltration to subjects undergoing open spinal fusion or reconstructive surgery. The secondary objectives of this study are to assess the safety, tolerability, and efficacy of EXPAREL in this surgical model.
Phase:
Phase 1
Details
Lead Sponsor:
Pacira Pharmaceuticals, Inc